Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin® litigation
<p>Abstract</p> <p>Background</p> <p>Previous studies have documented strategies to promote off-label use of drugs using journal publications and other means. Few studies have presented internal company communications that discussed financial reasons for manipulating th...
Main Authors: | Vedula S, Goldman Palko S, Rona Ilyas J, Greene Thomas M, Dickersin Kay |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-08-01
|
Series: | Trials |
Online Access: | http://www.trialsjournal.com/content/13/1/136 |
Similar Items
-
Gabapentin [Neurontin®]: Efficacy and Safety
by: J Gordon Millichap
Published: (1994-07-01) -
Differences in reporting of analyses in internal company documents versus published trial reports: comparisons in industry-sponsored trials in off-label uses of gabapentin.
by: S Swaroop Vedula, et al.
Published: (2013-01-01) -
The novel antiepileptic drug, gabapentin (Neurontin), binds to the α₂δ subunit of a voltage-dependent calcium channel
by: Brown, Jason Peter
Published: (1996) -
Biased under-reporting of research reflects biased under-submission more than biased editorial rejection [v1; ref status: indexed, http://f1000r.es/ViIqTX]
by: Iain Chalmers, et al.
Published: (2013-01-01) -
Who has used internal company documents for biomedical and public health research and where did they find them?
by: L Susan Wieland, et al.
Published: (2014-01-01)